valacyclovir plus aspirin
Phase 2Small molecule
GSKvalacyclovir plus aspirin is one of 34 small molecule programs targeting Genital Herpes. It is currently in Phase 2.
2
Indications
18
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
92 competitors in Herpes Zoster
#DrugCompanyPhaseTrials
1Fluzone
SanofiPhase 3
Herpes Zoster Vaccine 1437173a
GSKPhase 3
Rsvpref3 Vaccine
GSKPhase 3
GSK 257049
GSKPhase 3
Boostrix
GSKPhase 3
Prevenar13
GSKPhase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 2
Hz/su VACCINE
GSKPhase 3
Valaciclovir
GSKPhase 2
Influenza Vaccine
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Genital Herpes5 trials
Fed4 trials
Show 1 more trial
Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed Condition
Completed·—·Phase 1·NCT01136538·34 enrolled
Fasting Conditions2 trials
Aspirin1 trial
3 more indications
Herpes Simplex1 trial
Cytomegalovirus Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for valacyclovir plus aspirin. EMBL-EBI & Wellcome Sanger Institute.
- [4]